Role of melatonin in the treatment of depression
Depression remains a serious problem despite the continuous stream of researches on the problems of affective disorders and the emergence of new antidepressants. About 80% of inpatients with depression and 70% of outpatients with this condition complain of sleep disorders. There are presently a few...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2011-06-01
|
| Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/92 |
| id |
doaj-a8327cedf92e423d90f9feb67bc73b00 |
|---|---|
| record_format |
Article |
| spelling |
doaj-a8327cedf92e423d90f9feb67bc73b002021-07-29T08:58:32ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422011-06-0132858810.14412/2074-2711-2011-15392Role of melatonin in the treatment of depressionO. V. Kotova0I.M. Sechenov First Moscow State Medical UniversityDepression remains a serious problem despite the continuous stream of researches on the problems of affective disorders and the emergence of new antidepressants. About 80% of inpatients with depression and 70% of outpatients with this condition complain of sleep disorders. There are presently a few available hypotheses of the onset of depressive disorders. Prominent among them are neurotransmitter dysfunction hypotheses and chronobiological concepts (the presence of altered circadian rhythms mediated by melatonin). There is currently a wide range of drugs that are able to affect melatonin metabolism, amongst which there is agomelatine and fluvoxamine.https://nnp.ima-press.net/nnp/article/view/92depressioninsomniachronobiological theory of depressionagomelatinefluvoxamine |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
O. V. Kotova |
| spellingShingle |
O. V. Kotova Role of melatonin in the treatment of depression Nevrologiâ, Nejropsihiatriâ, Psihosomatika depression insomnia chronobiological theory of depression agomelatine fluvoxamine |
| author_facet |
O. V. Kotova |
| author_sort |
O. V. Kotova |
| title |
Role of melatonin in the treatment of depression |
| title_short |
Role of melatonin in the treatment of depression |
| title_full |
Role of melatonin in the treatment of depression |
| title_fullStr |
Role of melatonin in the treatment of depression |
| title_full_unstemmed |
Role of melatonin in the treatment of depression |
| title_sort |
role of melatonin in the treatment of depression |
| publisher |
IMA-PRESS LLC |
| series |
Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| issn |
2074-2711 2310-1342 |
| publishDate |
2011-06-01 |
| description |
Depression remains a serious problem despite the continuous stream of researches on the problems of affective disorders and the emergence of new antidepressants. About 80% of inpatients with depression and 70% of outpatients with this condition complain of sleep disorders. There are presently a few available hypotheses of the onset of depressive disorders. Prominent among them are neurotransmitter dysfunction hypotheses and chronobiological concepts (the presence of altered circadian rhythms mediated by melatonin). There is currently a wide range of drugs that are able to affect melatonin metabolism, amongst which there is agomelatine and fluvoxamine. |
| topic |
depression insomnia chronobiological theory of depression agomelatine fluvoxamine |
| url |
https://nnp.ima-press.net/nnp/article/view/92 |
| work_keys_str_mv |
AT ovkotova roleofmelatonininthetreatmentofdepression |
| _version_ |
1721250871256285184 |